{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:40:52Z","timestamp":1784644852988,"version":"3.55.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Posterior reversible encephalopathy syndrome (PRES) is a neurologic condition characterized by distinctive radiologic findings and altered mental status, often associated with chemotherapy or systemic endothelial dysfunction. To date, there have been no documented cases of PRES occurring after chimeric antigen receptor T cell therapy (CAR-T) for B-cell acute lymphoblastic leukemia (B-ALL). We describe the case of a 30-year-old female patient with relapsed B-ALL who received brexucabtagene autoleucel and subsequently developed a progressively worsening cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. On day 15 post-infusion, she developed acute encephalopathy and hypertension. The brain MRI revealed new, symmetric bilateral cortical and subcortical T2\/fluid-attenuated inversion recovery hyperintensities consistent with a diagnosis of PRES. Treatment with multiple courses of anti-seizure medications, anti-cytokine therapy, and high-dose pulse corticosteroids led to complete clinical recovery and resolution of the imaging abnormalities. To our knowledge, this represents the first reported case of PRES following CD19-directed CAR-T for B-ALL. This case highlights the potential for PRES as a complication of CAR-T mediated by cytokine-induced cerebrovascular endothelial injury. It also raises the possibility that a prior history of vasculitis, such as lymphomatoid granulomatosis, may predispose patients to an elevated risk of developing CAR-T-associated PRES.<\/jats:p>","DOI":"10.3389\/fonc.2025.1639892","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T04:10:57Z","timestamp":1757304657000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Posterior reversible encephalopathy syndrome after CD19 chimeric antigen receptor therapy for B-acute lymphoblastic leukemia: case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Rohan Dipesh","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranju","family":"Kunwor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya","family":"Sudanagunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin Hematol Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519671","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2024","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5702.5702","article-title":"Posterior reversible encephalopathy syndrome (PRES) after infusion of anti-bcma CAR T cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide","volume":"128","author":"Garfall","year":"2016","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050471","article-title":"Role of angiopoietin-2 in vascular physiology and pathophysiology","volume":"8","author":"Akwii","year":"2019","journal-title":"Cells"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00539","article-title":"Opposing roles of interferon-gamma on cells of the central nervous system in autoimmune neuroinflammation","volume":"6","author":"Ottum","year":"2015","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/861231","article-title":"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity","volume":"2014","author":"Olmos","year":"2014","journal-title":"Mediators Inflamm"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jon.13138","article-title":"Neuroimaging of complications arising after CD19 chimeric antigen receptor T-cell therapy: A review","volume":"33","author":"Pinto","year":"2023","journal-title":"J Neuroimaging"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1148\/rg.210065","article-title":"Imaging primer on chimeric antigen receptor T-cell therapy for radiologists","volume":"42","author":"de Groot","year":"2022","journal-title":"RadioGraphics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A0928","article-title":"Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features","volume":"29","author":"Bartynski","year":"2008","journal-title":"Am J Neuroradiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-012-0132-3","article-title":"Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes","volume":"7","author":"Dunleavy","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(05)80845-5","article-title":"Transient\u00a0ischemic cerebral lesions during induction chemotherapy for acute lymphoblastic leukemia","volume":"123","author":"Pihko","year":"1993","journal-title":"J Pediatr"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical\u00a0and\u00a0radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Advances"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0642-2","article-title":"Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children\u2019s Oncology Group Studies P9904 and P9905","volume":"34","author":"Winick","year":"2020","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"B16","volume-title":"Surveillance Research Program","year":"2025"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1639892\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T04:11:00Z","timestamp":1757304660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1639892\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":16,"alternative-id":["10.3389\/fonc.2025.1639892"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1639892","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"article-number":"1639892"}}